Sutro Biopharma, Inc.
Sutro Biopharma, Inc.（STRO）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · STRO · 截至 2026年6月9日
活动摘要
买入笔数
5
P-Purchase only
卖出笔数
0
近12个月
买卖比
∞
Buy/Sell (by trades)
整体情绪
Sutro Biopharma, Inc.内部人在过去近12个月净买入股份，可能反映对公司前景的信心。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
STRO 季度内部人买卖趋势
STRO 内幕交易卖出 · STRO 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · STRO CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
STRO 高管卖出股份 · STRO 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 2, 2026 | Chow Gregory K. CFO | Option | 2,500 | — | Form 4 |
| Mar 4, 2026 | Pauling David Chief Admin. Ofcr. & GC | Option | 675 | — | Form 4 |
| Mar 4, 2026 | Pauling David Chief Admin. Ofcr. & GC | Other | 277 | $6K | Form 4 |
| Mar 4, 2026 | Chung Jane CEO · Director | Option | 788 | — | Form 4 |
| Mar 4, 2026 | Chung Jane CEO · Director | Other | 282 | $6K | Form 4 |
| Mar 2, 2026 | Pauling David Chief Admin. Ofcr. & GC | Option | 2,356 | — | Form 4 |
| Mar 2, 2026 | Pauling David Chief Admin. Ofcr. & GC | Other | 970 | $20K | Form 4 |
| Mar 1, 2026 | Pauling David Chief Admin. Ofcr. & GC | Option | 842 | — | Form 4 |
| Mar 1, 2026 | Pauling David Chief Admin. Ofcr. & GC | Other | 551 | $11K | Form 4 |
| Mar 1, 2026 | Pauling David Chief Admin. Ofcr. & GC | Option | 500 | — | Form 4 |
| Mar 2, 2026 | Gerber Hans-Peter CHIEF SCIENTIFIC OFFICER | Option | 2,843 | — | Form 4 |
| Mar 2, 2026 | Gerber Hans-Peter CHIEF SCIENTIFIC OFFICER | Other | 1,170 | $24K | Form 4 |
| Mar 1, 2026 | Gerber Hans-Peter CHIEF SCIENTIFIC OFFICER | Option | 1,125 | — | Form 4 |
| Mar 1, 2026 | Gerber Hans-Peter CHIEF SCIENTIFIC OFFICER | Other | 463 | $9K | Form 4 |
| Mar 2, 2026 | Chung Jane CEO · Director | Option | 7,750 | — | Form 4 |
| Mar 2, 2026 | Chung Jane CEO · Director | Other | 2,779 | $57K | Form 4 |
| Mar 1, 2026 | Chung Jane CEO · Director | Option | 2,500 | — | Form 4 |
| Mar 1, 2026 | Chung Jane CEO · Director | Other | 1,271 | $26K | Form 4 |
| Mar 1, 2026 | Chung Jane CEO · Director | Option | 688 | — | Form 4 |
| Dec 12, 2025 | Chung Jane CEO · Director | Option | 2,500 | — | Form 4 |
| Dec 12, 2025 | Chung Jane CEO · Director | Other | 894 | $7K | Form 4 |
| Oct 15, 2025 | Gerber Hans-Peter CHIEF SCIENTIFIC OFFICER | Purchase | 17,000 | $14K | Form 4 |
| Oct 15, 2025 | Chow Gregory K. CFO | Purchase | 19,750 | $16K | Form 4 |
| Oct 15, 2025 | Chung Jane CEO · Director | Purchase | 12,500 | $10K | Form 4 |
| Oct 15, 2025 | MATSUI CONNIE Director | Purchase | 50,000 | $40K | Form 4 |
Gerber Hans-Peter
CHIEF SCIENTIFIC OFFICER
日期
Oct 15
股数
17,000
均价
$0.80
总金额
$14K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 STRO 内幕交易
STRO 内幕交易
Sutro Biopharma, Inc.（STRO）内幕交易数据来源于公司内部人（包括Chung Jane (CEO · Director), Pauling David (Chief Admin. Ofcr. & GC), Gerber Hans-Peter (CHIEF SCIENTIFIC OFFICER)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。STRO内部人近期主要在买入，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Sutro Biopharma, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
STRO 内幕交易 · 5个问题Sutro Biopharma, Inc.（STRO）的内部人包括高管和董事，如Chung Jane (CEO · Director), Pauling David (Chief Admin. Ofcr. & GC), Gerber Hans-Peter (CHIEF SCIENTIFIC OFFICER)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026